189 filings
Page 2 of 10
6-K
1jamzq6d28jo1jehe
4 Dec 23
Current report (foreign)
4:32pm
6-K
1piqft nxcuzkmo124mx
13 Nov 23
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
4:15pm
6-K
sk9b1boqw60oxhn9hl
9 Nov 23
Current report (foreign)
4:15pm
6-K
eiam 2363jo6
9 Nov 23
Voting Rights and Shares Capital of the Company
9:00am
6-K
2vn20115k6n
8 Nov 23
NANOBIOTIX Announces Closing of Global Offering
7:53am
6-K
ofis5h8ogb6axlr6o
7 Nov 23
Current report (foreign)
7:02am
424B5
n7drt7z0rb1
6 Nov 23
Prospectus supplement for primary offering
4:12pm
FWP
5fh7 hc0c7iyu9z
2 Nov 23
Free writing prospectus
4:36pm
6-K
se5jl 88fv7rp78q
2 Nov 23
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
10:56am
FWP
ufkspholm spi
2 Nov 23
Free writing prospectus
12:00am
424B5
6gggf1nc55fop ho4bh
1 Nov 23
Prospectus supplement for primary offering
6:50pm
6-K
phwqaz
1 Nov 23
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
6:36pm
6-K
tn092 c3dnj
23 Oct 23
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data
6:00am
6-K
5bd8wppf4 p5xmtu9
11 Oct 23
Voting Rights and Shares Capital of the Company
5:24pm
6-K
virntum087lrp0 0j3
4 Oct 23
Current report (foreign)
4:43pm
6-K
cnl qrzcle
29 Sep 23
Current report (foreign)
4:15pm
6-K
8ha97d awy2
28 Sep 23
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
4:15pm
6-K
uf9zp1pj2 xh
26 Sep 23
Current report (foreign)
4:33pm
6-K
i56v9lt2kdx9a0c1
26 Sep 23
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
4:15pm
6-K
4jx thm702lmlazbn07
19 Sep 23
Current report (foreign)
4:15pm